Relay Therapeutics

Come as you are at Relay Tx. Thanks to our Relay Resource Group, PaRTi, we celebrated #Pride this month with our favorite traditions: Pride trivia, drag bingo and our BAGLY, Inc. fundraiser. 🌈

Just published! We're excited to share our 2023 Corporate Responsibility report, which highlights our efforts to operate sustainably and responsibly. This year's report includes updates on our commitment to our patients, people, environment, community and governance. Check it out on our website. https://lnkd.in/gCxCKp_w

#ICYMI: Last week, we disclosed 3 new pre-clinical pipeline programs in #geneticdisease and solid tumors at our New Program & Platform Event. For full details on these programs and how the Dynamo™ platform led to these discoveries, access the webcast recording at the link below. https://lnkd.in/g79n8BnA

(9/9) We are focused on integrating industry-leading tools into our world-class Dynamo™ platform to continue rapidly growing and evolving. This morning’s New Program & Platform event underscored the potential for our pipeline programs to help many patients in need. Learn more about the new programs we announced earlier today here. https://lnkd.in/eFccCmAw

(8/9) By the end of 2025, we expect all 3 of these new programs to have entered the clinic. If so, this would total 11 development candidates, 7 Investigational New Drug Applications and 7 programs to have entered the clinic in the first decade of Relay Therapeutics’ history. The power of our Dynamo™ platform will continue to drive the next wave of Relay Tx’s growth and innovation in drug discovery.

(7/9) About 28,000 people in the U.S. are diagnosed each year with NRAS-mutant solid tumors, including #melanoma, #NSCLC and #CRC. Existing treatments either target all RAS proteins (pan-RAS), or target other downstream parts of the pathway, which leads to significant off-target toxicity and limits efficacy. We have created the first NRAS-selective inhibitor, which has been designed to address the liabilities of current pan-RAS inhibitors by only binding to NRAS. We expect to initiate clinical development of this inhibitor in the second half of 2025.

(6/9) We are excited to disclose our second genetic disease program: Fabry disease. In #Fabrydisease, which effects approximately 8,000 people in the U.S., harmful levels of Gb3 accumulate in blood cells and tissues throughout the body, due to insufficient αGal enzyme activity, which can lead to a range of symptoms, including potentially life-threatening ones such as kidney failure, heart failure and stroke.     We have created the first non-inhibitory chaperone, which is designed to stabilize the αGal protein without inhibiting its activity, thus enabling greater Gb3 clearance across organs. We expect this program to enter the clinic in the second half of 2025.

(5/9) Live from our New Program and Platform Event: Vascular Malformations expert, Dr. Adrienne Hammill, associate professor at University of Cincinnati College of Medicine and physician at Cincinnati Children's, discusses her clinical experience treating patients with vascular malformations, including the limitations of current systemic therapy options.

(4/9) PI3Kα-Driven Vascular Malformations is the first of two programs in #geneticdisease that we unveiled today. #Vascularmalformations are a series of rare syndromes that occur due to atypical development of lymphatic and/or blood vessels, of which mutant PI3Kα is the most common driver. There are over ~170,000 patients with PI3Kα-driven vascular malformations in the U.S. We believe our mutant-selective PI3Kα inhibitor, RLY-2608, provides the opportunity for greater target coverage, leading to the potential for improved efficacy and better chronic tolerability for these patients. We plan to initiate clinical development in Q1 2025.

(3/9) We have built our world-class Dynamo™ platform to combine experimental and computational techniques, tools and team members. This has resulted in 8 drug candidates and 4 Investigational New Drug Applications since the founding of the company 8 years ago. Today, CEO Sanjiv Patel shared more about Dynamo’s integral role in our ambitions to develop medicines for patients in need.